Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?
Identifieur interne : 000273 ( PubMed/Corpus ); précédent : 000272; suivant : 000274Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?
Auteurs : Romain Lefaucheur ; Floriane Le Goff ; Gaëlle Gaillon ; Aude Triquenot-Bagan ; David MaltêteSource :
- Presse medicale (Paris, France : 1983) [ 2213-0276 ] ; 2015.
English descriptors
- KwdEn :
- Anticoagulants (therapeutic use), Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), Biotransformation, Dizziness (chemically induced), Drug Interactions, Drug Substitution, Drug Therapy, Combination, Factor Xa Inhibitors (adverse effects), Factor Xa Inhibitors (pharmacokinetics), Factor Xa Inhibitors (therapeutic use), Humans, Indans (adverse effects), Indans (pharmacokinetics), Indans (therapeutic use), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Rivaroxaban (adverse effects), Rivaroxaban (pharmacokinetics), Rivaroxaban (therapeutic use), Trihexyphenidyl (adverse effects), Trihexyphenidyl (pharmacokinetics), Trihexyphenidyl (therapeutic use), Venous Thrombosis (complications), Venous Thrombosis (drug therapy), Warfarin (therapeutic use).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Factor Xa Inhibitors, Indans, Rivaroxaban, Trihexyphenidyl.
- chemical , pharmacokinetics : Antiparkinson Agents, Factor Xa Inhibitors, Indans, Rivaroxaban, Trihexyphenidyl.
- chemical , therapeutic use : Anticoagulants, Antiparkinson Agents, Factor Xa Inhibitors, Indans, Rivaroxaban, Trihexyphenidyl, Warfarin.
- chemically induced : Dizziness.
- complications : Parkinson Disease, Venous Thrombosis.
- drug therapy : Parkinson Disease, Venous Thrombosis.
- Biotransformation, Drug Interactions, Drug Substitution, Drug Therapy, Combination, Humans, Male, Middle Aged.
DOI: 10.1016/j.lpm.2015.09.007
PubMed: 26433836
Links to Exploration step
pubmed:26433836Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?</title><author><name sortKey="Lefaucheur, Romain" sort="Lefaucheur, Romain" uniqKey="Lefaucheur R" first="Romain" last="Lefaucheur">Romain Lefaucheur</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France. Electronic address: romain.lefaucheur@chu-rouen.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Le Goff, Floriane" sort="Le Goff, Floriane" uniqKey="Le Goff F" first="Floriane" last="Le Goff">Floriane Le Goff</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gaillon, Gaelle" sort="Gaillon, Gaelle" uniqKey="Gaillon G" first="Gaëlle" last="Gaillon">Gaëlle Gaillon</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Pharmacology, Rouen, France.</nlm:affiliation></affiliation></author><author><name sortKey="Triquenot Bagan, Aude" sort="Triquenot Bagan, Aude" uniqKey="Triquenot Bagan A" first="Aude" last="Triquenot-Bagan">Aude Triquenot-Bagan</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France.</nlm:affiliation></affiliation></author><author><name sortKey="Maltete, David" sort="Maltete, David" uniqKey="Maltete D" first="David" last="Maltête">David Maltête</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France; Inserm U1079, Rouen Faculty of Medicine, Rouen, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26433836</idno><idno type="pmid">26433836</idno><idno type="doi">10.1016/j.lpm.2015.09.007</idno><idno type="wicri:Area/PubMed/Corpus">000273</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000273</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?</title><author><name sortKey="Lefaucheur, Romain" sort="Lefaucheur, Romain" uniqKey="Lefaucheur R" first="Romain" last="Lefaucheur">Romain Lefaucheur</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France. Electronic address: romain.lefaucheur@chu-rouen.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Le Goff, Floriane" sort="Le Goff, Floriane" uniqKey="Le Goff F" first="Floriane" last="Le Goff">Floriane Le Goff</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gaillon, Gaelle" sort="Gaillon, Gaelle" uniqKey="Gaillon G" first="Gaëlle" last="Gaillon">Gaëlle Gaillon</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Pharmacology, Rouen, France.</nlm:affiliation></affiliation></author><author><name sortKey="Triquenot Bagan, Aude" sort="Triquenot Bagan, Aude" uniqKey="Triquenot Bagan A" first="Aude" last="Triquenot-Bagan">Aude Triquenot-Bagan</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France.</nlm:affiliation></affiliation></author><author><name sortKey="Maltete, David" sort="Maltete, David" uniqKey="Maltete D" first="David" last="Maltête">David Maltête</name><affiliation><nlm:affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France; Inserm U1079, Rouen Faculty of Medicine, Rouen, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Presse medicale (Paris, France : 1983)</title><idno type="eISSN">2213-0276</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticoagulants (therapeutic use)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Biotransformation</term><term>Dizziness (chemically induced)</term><term>Drug Interactions</term><term>Drug Substitution</term><term>Drug Therapy, Combination</term><term>Factor Xa Inhibitors (adverse effects)</term><term>Factor Xa Inhibitors (pharmacokinetics)</term><term>Factor Xa Inhibitors (therapeutic use)</term><term>Humans</term><term>Indans (adverse effects)</term><term>Indans (pharmacokinetics)</term><term>Indans (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Rivaroxaban (adverse effects)</term><term>Rivaroxaban (pharmacokinetics)</term><term>Rivaroxaban (therapeutic use)</term><term>Trihexyphenidyl (adverse effects)</term><term>Trihexyphenidyl (pharmacokinetics)</term><term>Trihexyphenidyl (therapeutic use)</term><term>Venous Thrombosis (complications)</term><term>Venous Thrombosis (drug therapy)</term><term>Warfarin (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Factor Xa Inhibitors</term><term>Indans</term><term>Rivaroxaban</term><term>Trihexyphenidyl</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Factor Xa Inhibitors</term><term>Indans</term><term>Rivaroxaban</term><term>Trihexyphenidyl</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticoagulants</term><term>Antiparkinson Agents</term><term>Factor Xa Inhibitors</term><term>Indans</term><term>Rivaroxaban</term><term>Trihexyphenidyl</term><term>Warfarin</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Dizziness</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term><term>Venous Thrombosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Venous Thrombosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Biotransformation</term><term>Drug Interactions</term><term>Drug Substitution</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26433836</PMID><DateCreated><Year>2015</Year><Month>11</Month><Day>29</Day></DateCreated><DateCompleted><Year>2016</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2213-0276</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>11</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Presse medicale (Paris, France : 1983)</Title><ISOAbbreviation>Presse Med</ISOAbbreviation></Journal><ArticleTitle>Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?</ArticleTitle><Pagination><MedlinePgn>1203-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lpm.2015.09.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0755-4982(15)00399-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lefaucheur</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France. Electronic address: romain.lefaucheur@chu-rouen.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Goff</LastName><ForeName>Floriane</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaillon</LastName><ForeName>Gaëlle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Rouen University Hospital and University of Rouen, Department of Pharmacology, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Triquenot-Bagan</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maltête</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rouen University Hospital and University of Rouen, Department of Neurology, 76031 Rouen cedex, France; Inserm U1079, Rouen Faculty of Medicine, Rouen, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Presse Med</MedlineTA><NlmUniqueID>8302490</NlmUniqueID><ISSNLinking>0755-4982</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical><Chemical><RegistryNumber>6RC5V8B7PO</RegistryNumber><NameOfSubstance UI="D014282">Trihexyphenidyl</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001711" MajorTopicYN="N">Biotransformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004244" MajorTopicYN="N">Dizziness</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065427" MajorTopicYN="N">Factor Xa Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014282" MajorTopicYN="N">Trihexyphenidyl</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>07</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>08</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26433836</ArticleId><ArticleId IdType="pii">S0755-4982(15)00399-1</ArticleId><ArticleId IdType="doi">10.1016/j.lpm.2015.09.007</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000273 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000273 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26433836
|texte= Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26433836" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |